The_DT financial_JJ statements_NNS of_IN the_DT Group_NNP are_VBP prepared_VBN in_IN accordance_NN with_IN UK_NNP GAAP_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNS which_WDT differs_VBZ in_IN certain_JJ respects_NNS from_IN US_NNP GAAP_NNP ._.
The_DT tables_NNS below_IN summarise_NN the_DT material_NN adjustments_NNS to_TO the_DT loss_NN for_IN the_DT year_NN and_CC shareholders_NNS funds_NNS which_WDT would_MD be_VB required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD Notes_NNP 000_CD 000_CD Profit_NN loss_NN under_IN UK_NNP GAAP_NNP 1,109_CD 9,452_CD US_NNP GAAP_NNP adjustments_NNS :_: Purchase_NN accounting_NN and_CC goodwill_NN Amortisation_NNP of_IN goodwill_NN and_CC other_JJ intangibles_NNS I_PRP 3,399_CD 5,708_CD Depreciation_NN of_IN tangible_JJ fixed_JJ assets_NNS II_NNP 518_CD 488_CD Write-off_NN of_IN acquired_VBN in-process_JJ research_NN and_CC development_NN costs_NNS III_NNP 4,646_CD 18,893_CD Results_NNS in_IN equity_NN investments_NNS RTP_NNP III_NNP 559_CD Deferred_JJ taxes_NNS III_NNP 401_CD Share-based_JJ compensation_NN IX_CD 181_CD 215_CD Revenue_NN recognition_NN VII_NNP 26,987_CD 1,934_CD Sale_NNP of_IN royalty_NN interests_NNS Revenue_NN recognition_NN VIII_NNP 14,219_CD 6,342_CD Interest_NN expense_NN VIII_NNP 5,850_CD 1,222_CD Royalty_NN payments_NNS VIII_NNP 664_CD Financial_NNP instruments_NNS XI_NNP 531_CD 31_CD Net_JJ loss_NN under_IN US_NNP GAAP_NNP 45,261_CD 43,868_CD Net_JJ loss_NN per_IN Ordinary_NNP Share_NNP under_IN US_NNP GAAP_NNP pence_NN 7.8_CD p_NN 8.3_CD p_NN Shareholders_NNS funds_NNS Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2002_CD 31_CD December_NNP 2001_CD Notes_NNP 000_CD 000_CD Shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP 124,270_CD 95,145_CD US_NNP GAAP_NNP adjustments_NNS :_: Purchase_NN accounting_NN and_CC goodwill_NN Goodwill_NNP I_PRP ,_, III_NNP 83,719_CD 73,259_CD Other_JJ intangible_JJ fixed_JJ assets_NNS I_PRP 4,344_CD 5,174_CD Tangible_JJ fixed_JJ assets_NNS II_NNP 7,930_CD 7,192_CD Investments_NNP III_NNP 1,893_CD 796_CD Deferred_JJ taxes_NNS III_NNP 1,439_CD 2,738_CD Contingent_JJ consideration_NN charged_VBN to_TO goodwill_NN reserve_NN V_NNP 22,620_CD 27,457_CD Shares_NNS issued_VBN relating_VBG to_TO contingent_JJ consideration_NN VI_NNP 11,310_CD Shares_NNP and_CC warrants_NNS to_TO be_VB issued_VBN ,_, deferred_VBN shares_NNS and_CC shares_NNS issued_VBN to_TO Dr_NNP Gonella_NNP IV_NNP 11,310_CD 34,070_CD Share-based_JJ compensation_NN IX_CD 305_CD 193_CD Employee_NNP Benefit_NNP Trust_NNP X_NNP 1,859_CD 552_CD Deferred_JJ revenue_NN VII_NNP 23,179_CD 771_CD Funding_NNP liabilities_NNS VIII_NNP 37,698_CD 15,256_CD Financial_NNP instruments_NNS XI_NNP 500_CD 31_CD Shareholders_NNS funds_NNS under_IN US_NNP GAAP_NNP 138,530_CD 142,570_CD reconciliation_NN to_TO US_NNP 82_CD accounting_NN principles_NNS SkyePharma_NNP annual_JJ report_NN 2002_CD SkyePharma_NNP annual_JJ report_NN 2002_CD Summary_NNP of_IN Material_NNP Differences_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP Under_IN US_NNP GAAP_NNP ,_, contingent_JJ consideration_NN is_VBZ recognized_VBN only_RB when_WRB determinable_JJ beyond_IN reasonable_JJ doubt_NN ,_, therefore_RB deferred_VBN shares_NNS I_PRP Goodwill_NNP and_CC other_JJ intangible_JJ fixed_JJ assets_NNS Prior_RB to_TO the_DT introduction_NN of_IN and_CC shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN have_VBP been_VBN reversed_VBN out_IN of_IN FRS10_NNP ,_, as_IN permissible_JJ under_IN UK_NNP GAAP_NNP ,_, no_DT intangible_JJ assets_NNS had_VBD been_VBN shareholders_NNS funds_NNS under_IN US_NNP GAAP_NNP ._.
recognized_VBN as_IN a_DT result_NN of_IN purchase_NN accounting_NN as_IN the_DT intangible_JJ assets_NNS In_IN addition_NN ,_, under_IN UK_NNP GAAP_NNP in_IN connection_NN with_IN the_DT acquisition_NN of_IN RTP_NNP ,_, were_VBD considered_VBN to_TO be_VB an_DT integral_JJ part_NN of_IN the_DT business_NN acquired_VBD and_CC 5.8_CD million_CD of_IN the_DT total_JJ consideration_NN was_VBD payable_JJ in_IN shares_NNS which_WDT were_VBD were_VBD ,_, therefore_RB ,_, included_VBD within_IN goodwill_NN and_CC eliminated_VBN against_IN issued_VBN subsequent_JJ to_TO 31_CD December_NNP 2001_CD ._.
As_IN of_IN 31_CD December_NNP 2001_CD ,_, these_DT shareholders_NNS funds_NNS ._.
Where_WRB the_DT aggregate_NN of_IN the_DT fair_JJ values_NNS of_IN the_DT net_JJ shares_NNS had_VBD been_VBN included_VBN within_IN shareholders_NNS funds_NNS and_CC warrants_NNS to_TO be_VB assets_NNS acquired_VBN exceeded_VBD the_DT cost_NN of_IN the_DT acquired_VBN net_JJ assets_NNS resulting_VBG issued_VBN ._.
Under_IN US_NNP GAAP_NNP ,_, such_JJ amounts_NNS would_MD be_VB recorded_VBN as_IN a_DT liability_NN in_IN negative_JJ goodwill_NN ,_, such_JJ excess_NN was_VBD credited_VBN directly_RB to_TO reserves_NNS ._.
The_DT until_IN the_DT shares_NNS are_VBP issued_VBN ._.
Group_NNP adopted_VBD transitional_JJ provisions_NNS under_IN FRS10_NNP and_CC accordingly_RB did_VBD V_NNP Contingent_NNP consideration_NN charged_VBD to_TO goodwill_NN The_DT Group_NNP effected_VBD the_DT not_RB reinstate_VB goodwill_NN previously_RB eliminated_VBN against_IN reserves_NNS as_IN an_DT acquisition_NN of_IN Krypton_NNP and_CC Jago_NNP through_IN the_DT exchange_NN of_IN warrants_NNS and_CC intangible_JJ asset_NN ._.
The_DT issuance_NN of_IN certain_JJ of_IN these_DT warrants_NNS and_CC shares_NNS is_VBZ US_NNP GAAP_NNP requires_VBZ an_DT allocation_NN of_IN the_DT purchase_NN consideration_NN to_TO contingent_JJ upon_IN the_DT occurrence_NN of_IN certain_JJ future_JJ events_NNS ._.
Under_IN UK_NNP identifiable_JJ intangible_JJ assets_NNS ,_, including_VBG any_DT resulting_VBG from_IN research_NN GAAP_NNP ,_, the_DT Group_NNP estimated_VBD the_DT fair_JJ value_NN of_IN the_DT contingent_JJ consideration_NN and_CC development_NN ._.
Goodwill_NN and_CC identifiable_JJ intangible_JJ fixed_JJ assets_NNS are_VBP to_TO determine_VB the_DT acquisition_NN cost_NN ._.
The_DT resulting_VBG goodwill_NN was_VBD eliminated_VBN reflected_VBN as_IN assets_NNS ._.
Prior_RB to_TO 2002_CD ,_, goodwill_NN was_VBD amortised_VBN over_IN its_PRP$ useful_JJ against_IN shareholders_NNS funds_NNS ._.
life_NN ,_, with_IN the_DT exception_NN of_IN goodwill_NN arising_VBG on_IN acquisitions_NNS made_VBN after_IN Under_IN US_NNP GAAP_NNP the_DT acquisition_NN cost_NN has_VBZ been_VBN adjusted_VBN to_TO remove_VB 30_CD June_NNP 2001_CD ._.
Effective_JJ 1_CD January_NNP 2002_CD goodwill_NN is_VBZ no_RB longer_RBR amortised_VBN the_DT contingent_JJ consideration_NN ,_, which_WDT is_VBZ only_RB recognized_VBN when_WRB it_PRP under_IN US_NNP GAAP_NNP ,_, but_CC instead_RB subject_JJ to_TO annual_JJ impairment_NN tests_NNS ._.
This_DT is_VBZ determinable_JJ beyond_IN reasonable_JJ doubt_NN ,_, therefore_RB contingent_JJ results_NNS in_IN a_DT reversal_NN of_IN goodwill_NN amortisation_NN charged_VBN under_IN UK_NNP GAAP_NNP ._.
consideration_NN charged_VBD to_TO goodwill_NN reserves_NNS has_VBZ been_VBN reversed_JJ Intangible_JJ fixed_JJ assets_NNS recognized_VBN under_IN US_NNP GAAP_NNP purchase_NN accounting_NN out_IN of_IN shareholders_NNS funds_NNS under_IN US_NNP GAAP_NNP ._.
requirements_NNS are_VBP amortised_VBN over_IN their_PRP$ estimated_VBN revenue_NN earning_VBG life_NN ._.
Negative_JJ goodwill_NN ,_, if_IN any_DT ,_, is_VBZ eliminated_VBN by_IN reducing_VBG the_DT value_NN of_IN all_DT VI_NNP Shares_NNP issued_VBD related_VBN to_TO contingent_JJ consideration_NN In_IN April_NNP 2002_CD ,_, all_DT non-current_JJ assets_NNS acquired_VBN ._.
contingencies_NNS related_VBN to_TO the_DT Deferred_NNP A_NNP Shares_NNP were_VBD removed_VBN based_VBN on_IN the_DT first_JJ commercial_JJ launch_NN of_IN Paxil_NNP CR_NNP ._.
In_IN connection_NN with_IN the_DT removal_NN II_NNP Tangible_JJ fixed_VBN assets_NNS Prior_RB to_TO the_DT introduction_NN of_IN FRS10_CD under_IN UK_NNP GAAP_NNP of_IN these_DT contingencies_NNS ,_, in_IN 2002_CD the_DT Group_NNP issued_VBD 12_CD million_CD Ordinary_NNP for_IN business_NN acquisitions_NNS ,_, where_WRB the_DT aggregate_NN of_IN the_DT fair_JJ values_NNS of_IN Shares_NNS to_TO Dr._NNP Gonella_NNP ,_, the_DT vendor_NN of_IN Jago_NNP ._.
Under_IN US_NNP GAAP_NNP ,_, these_DT shares_NNS the_DT net_JJ assets_NNS acquired_VBN exceeded_VBD the_DT cost_NN of_IN the_DT acquired_VBN net_JJ assets_NNS were_VBD recorded_VBN within_IN shareholders_NNS funds_NNS at_IN the_DT market_NN value_NN at_IN the_DT date_NN resulting_VBG in_IN negative_JJ goodwill_NN ,_, such_JJ excess_NN was_VBD credited_VBN directly_RB to_TO the_DT contingencies_NNS were_VBD removed_VBN ._.
Under_IN US_NNP GAAP_NNP such_JJ excess_NN is_VBZ eliminated_VBN by_IN proportionately_RB reducing_VBG the_DT value_NN of_IN the_DT non-current_JJ assets_NNS acquired_VBN ._.
Under_IN UK_NNP GAAP_NNP the_DT shares_NNS were_VBD recorded_VBN at_IN the_DT market_NN price_NN at_IN the_DT date_NN of_IN issuance_NN of_IN deferred_JJ shares_NNS 20_CD July_NNP 2000_CD ._.
The_DT adjustment_NN III_NNP Acquired_VBD in-process_JJ research_NN and_CC development_NN costs_NNS The_DT Group_NNP reverses_VBZ the_DT value_NN of_IN equity_NN share_NN capital_NN and_CC premium_NN in_IN the_DT amount_NN of_IN acquired_VBN the_DT drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP for_IN 3.6_CD million_CD and_CC 11.3_CD million_CD ._.
A_DT corresponding_JJ adjustment_NN in_IN the_DT amount_NN of_IN 9.4_CD million_CD the_DT assumption_NN of_IN 0.4_CD million_CD of_IN net_JJ liabilities_NNS in_IN May_NNP 2002_CD ,_, as_IN described_VBN has_VBZ been_VBN recorded_VBN within_IN Goodwill_NNP and_CC other_JJ intangible_JJ fixed_JJ assets_NNS that_IN in_IN note_NN 27_CD :_: Acquisitions_NNS ._.
In_IN determining_VBG the_DT allocation_NN of_IN the_DT purchase_NN represents_VBZ the_DT fair_JJ value_NN of_IN shares_NNS issued_VBN under_IN US_NNP GAAP_NNP ._.
price_NN to_TO assets_NNS and_CC liabilities_NNS acquired_VBN ,_, the_DT Group_NNP valued_VBN acquired_VBN inprocess_JJ research_NN and_CC development_NN that_WDT had_VBD no_DT other_JJ alternative_JJ use_NN at_IN VII_NNP Revenue_NNP recognition_NN Under_IN US_NNP GAAP_NNP ,_, more_JJR prescriptive_JJ criteria_NNS than_IN 5.1_CD million_CD which_WDT created_VBD negative_JJ goodwill_NN of_IN 1.1_CD million_CD which_WDT was_VBD UK_NNP GAAP_NNP have_VBP been_VBN applied_VBN to_TO assess_VB whether_IN the_DT culmination_NN of_IN the_DT allocated_VBN among_IN non-current_JJ assets_NNS acquired_VBN ._.
Accordingly_RB ,_, the_DT fair_JJ value_NN earnings_NNS process_NN has_VBZ been_VBN completed_VBN and_CC whether_IN the_DT Group_NNP has_VBZ of_IN non-current_JJ asset_NN acquired_VBN in_IN the_DT amount_NN of_IN 0.7_CD million_CD was_VBD reduced_VBN continuing_VBG obligations_NNS throughout_IN the_DT contract_NN term_NN ._.
As_IN a_DT result_NN ,_, under_IN to_TO nil_VB and_CC 4.6_CD million_CD of_IN in-process_JJ research_NN and_CC development_NN was_VBD US_NNP GAAP_NNP certain_JJ non-refundable_JJ up-front_JJ payments_NNS have_VBP been_VBN deferred_VBN expensed_VBN in_IN the_DT period_NN of_IN acquisition_NN ._.
over_IN the_DT development_NN period_NN of_IN the_DT contract_NN term_NN on_IN certain_JJ agreements_NNS ._.
In_IN 2001_CD ,_, the_DT Group_NNP purchased_VBD the_DT majority_NN interest_NN of_IN RTP_NNP through_IN a_DT twoDeferred_JJ revenue_NN reflects_VBZ the_DT amount_NN of_IN revenue_NN not_RB currently_RB eligible_JJ for_IN step_NN acquisition_NN effected_VBD in_IN July_NNP and_CC December_NNP 2001_CD ._.
The_DT acquisition_NN was_VBD recognition_NN under_IN US_NNP GAAP_NNP as_RB well_RB as_IN the_DT reversal_NN of_IN 7.8_CD million_CD 4.8_CD recorded_VBN using_VBG the_DT purchase_NN method_NN of_IN accounting_NN under_IN both_DT UK_NNP and_CC million_CD as_IN of_IN 31_CD December_NNP 2001_CD deferred_JJ revenue_NN under_IN UK_NNP GAAP_NNP related_JJ US_NNP GAAP_NNP ._.
to_TO the_DT sale_NN of_IN royalty_NN interests_NNS ,_, which_WDT is_VBZ treated_VBN as_IN debt_NN under_IN US_NNP GAAP_NNP ._.
The_DT adjustments_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP in_IN respect_NN of_IN the_DT RTP_NNP VIII_NNP Sale_NNP of_IN royalty_NN interests_NNS Under_IN UK_NNP GAAP_NNP payments_NNS received_VBD from_IN a_DT acquisition_NN relate_VB mainly_RB to_TO differences_NNS in_IN the_DT valuation_NN of_IN purchase_NN third_JJ party_NN to_TO fund_VB the_DT internal_JJ research_NN and_CC development_NN of_IN a_DT product_NN in_IN price_NN consideration_NN ,_, the_DT methods_NNS of_IN purchase_NN price_NN allocation_NN and_CC the_DT return_NN for_IN the_DT sale_NN of_IN a_DT proportion_NN of_IN potential_JJ future_JJ royalty_NN streams_NNS from_IN amortisation_NN of_IN goodwill_NN ._.
In_IN 2001_CD ,_, this_DT resulted_VBD in_IN a_DT 5.3_CD million_CD increase_NN a_DT selection_NN of_IN products_NNS are_VBP reflected_VBN within_IN other_JJ operating_NN income_NN when_WRB in_IN purchase_NN consideration_NN and_CC differences_NNS in_IN the_DT amounts_NNS assigned_VBN to_TO the_DT risk_NN of_IN reimbursement_NN has_VBZ effectively_RB been_VBN transferred_VBN to_TO the_DT third_JJ certain_JJ tangible_JJ and_CC intangible_JJ fixed_VBN assets_NNS ,_, investments_NNS and_CC related_VBN party_NN ._.
Royalties_NNS repaid_VBN to_TO third_JJ parties_NNS are_VBP treated_VBN as_IN cost_NN of_IN goods_NNS sold_VBN ._.
Under_IN US_NNP GAAP_NNP amounts_VBZ allocated_VBN to_TO acquired_VBN in-process_JJ US_NNP GAAP_NNP requires_VBZ such_JJ funding_NN payments_NNS to_TO be_VB recorded_VBN as_IN debt_NN where_WRB research_NN and_CC development_NN that_WDT do_VBP not_RB have_VB an_DT alternative_JJ use_NN have_VBP been_VBN there_EX is_VBZ continuing_VBG involvement_NN in_IN the_DT generation_NN of_IN the_DT cash_NN flows_VBZ due_JJ to_TO expensed_VBN through_IN earnings_NNS in_IN the_DT period_NN of_IN acquisition_NN :_: under_IN UK_NNP GAAP_NNP ,_, the_DT third_JJ party_NN ._.
The_DT US_NNP GAAP_NNP adjustment_NN for_IN the_DT statement_NN of_IN operations_NNS certain_JJ of_IN these_DT amounts_NNS are_VBP not_RB separately_RB identified_VBN but_CC considered_VBN includes_VBZ the_DT reversal_NN of_IN funding_NN revenue_NN recorded_VBN from_IN the_DT third_JJ party_NN as_IN part_NN of_IN goodwill_NN ._.
In_IN addition_NN ,_, under_IN UK_NNP GAAP_NNP goodwill_NN is_VBZ being_VBG amortised_VBN well_RB as_IN recording_VBG the_DT interest_NN charge_NN for_IN the_DT period_NN on_IN the_DT outstanding_JJ over_IN 20_CD years_NNS on_IN a_DT straight-line_JJ basis_NN while_IN under_IN US_NNP GAAP_NNP ,_, goodwill_NN funding_NN liability_NN balance_NN ._.
Repayments_NNS made_VBD to_TO third_JJ parties_NNS in_IN the_DT form_NN of_IN resulting_VBG from_IN this_DT acquisition_NN was_VBD not_RB amortised_VBN ._.
royalty_NN payments_NNS that_WDT are_VBP expensed_VBN under_IN UK_NNP GAAP_NNP are_VBP reversed_VBN under_IN IV_NNP Deferred_NNP shares_NNS and_CC shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN Under_IN UK_NNP GAAP_NNP ,_, US_NNP GAAP_NNP since_IN they_PRP are_VBP treated_VBN as_IN repayment_NN of_IN debt_NN ._.
contingent_JJ consideration_NN payable_JJ in_IN connection_NN with_IN the_DT acquisition_NN IX_CD Share-based_JJ compensation_NN Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP applies_VBZ of_IN Jago_NNP is_VBZ included_VBN within_IN shareholders_NNS funds_NNS as_IN deferred_JJ shares_NNS ._.
Accounting_NNP Principles_NNP Board_NNP Opinion_NNP APB_NNP No._NN ._.
25_CD ,_, Accounting_NNP for_IN Stock_NNP As_IN of_IN 31_CD December_NNP 2001_CD ,_, the_DT Group_NNP had_VBD also_RB recorded_VBN contingent_JJ Issued_VBN to_TO Employees_NNS ,_, and_CC related_JJ interpretations_NNS in_IN accounting_NN for_IN its_PRP$ consideration_NN payable_JJ within_IN shareholders_NNS funds_NNS in_IN the_DT amount_NN of_IN plans_NNS ._.
Accordingly_RB ,_, a_DT compensation_NN expense_NN has_VBZ been_VBN recognized_VBN for_IN 4.8_CD million_CD in_IN connection_NN with_IN the_DT acquisition_NN of_IN Krypton_NNP ._.
The_DT amount_NN performance-based_JJ compensation_NN plans_NNS where_WRB it_PRP is_VBZ probable_JJ that_IN the_DT at_IN 31_CD December_NNP 2002_CD related_VBN to_TO Krypton_NNP was_VBD nil_NN ._.
83_CD Summary_NNP of_IN Material_NNP Differences_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP continued_VBD XIII_NNP Recent_JJ U._NNP S._NNP GAAP_NNP Pronouncements_NNP In_IN August_NNP 2001_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
143_CD ,_, Accounting_NNP for_IN Obligations_NNS Associated_NNP with_IN the_DT performance_NN criteria_NNS will_MD be_VB met_VBN and_CC the_DT options_NNS exercised_VBN prior_RB to_TO the_DT Retirement_NNP of_IN Long-Lived_NNP Assets_NNPS ._.
This_DT standard_NN will_MD be_VB effective_JJ for_IN the_DT expiration_NN of_IN the_DT options_NNS issued_VBN under_IN these_DT plans_NNS ._.
No_DT compensation_NN Groups_NNS fiscal_JJ year_NN beginning_VBG 1_CD January_NNP 2003_CD ._.
The_DT standard_JJ requires_VBZ that_IN expense_NN has_VBZ been_VBN recognized_VBN for_IN those_DT plans_NNS that_WDT are_VBP considered_VBN fixed_VBN such_JJ obligations_NNS be_VB capitalized_VBN as_IN part_NN of_IN the_DT assets_NNS cost_NN at_IN the_DT time_NN of_IN option_NN plans_NNS under_IN APB_NNP 25_CD and_CC where_WRB the_DT options_NNS granted_VBN under_IN the_DT plans_NNS initial_JJ recognition_NN ,_, with_IN the_DT related_VBN liability_NN discounted_VBN to_TO its_PRP$ fair_JJ value_NN at_IN are_VBP granted_VBN at_IN a_DT price_NN that_WDT equals_VBZ the_DT market_NN price_NN at_IN the_DT date_NN of_IN grant_NN ._.
The_DT income_NN statement_NN impact_NN of_IN adopting_VBG this_DT X_NNP Employee_NNP Benefit_NNP Trust_NNP Under_IN UK_NNP GAAP_NNP the_DT Ordinary_NNP Shares_NNP of_IN the_DT standard_NN will_MD be_VB presented_VBN as_IN a_DT cumulative_JJ effect_NN of_IN a_DT change_NN in_IN Company_NN held_VBN by_IN the_DT SkyePharma_NNP PLC_NNP General_NNP Employee_NNP Benefit_NNP Trust_NNP accounting_NN principle_NN ._.
The_DT Group_NNP does_VBZ not_RB believe_VB the_DT adoption_NN of_IN this_DT are_VBP recorded_VBN at_IN cost_NN and_CC accounted_VBD for_IN as_IN investments_NNS ._.
The_DT value_NN of_IN standard_NN will_MD have_VB a_DT material_NN impact_NN on_IN its_PRP$ financial_JJ position_NN or_CC results_NNS shares_NNS and_CC options_NNS granted_VBN are_VBP deducted_VBN from_IN the_DT cost_NN value_NN of_IN shares_NNS of_IN operations_NNS ._.
held_VBN in_IN the_DT Employee_NNP Benefit_NNP Trust_NNP and_CC charged_VBN to_TO current_JJ period_NN In_IN April_NNP 2002_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
This_DT standard_NN will_MD require_VB expense_NN or_CC over_IN the_DT vesting_JJ period_NN if_IN options_NNS vest_NN over_IN a_DT period_NN of_IN time_NN ._.
gains_NNS and_CC losses_NNS from_IN extinguishment_NN of_IN debt_NN to_TO be_VB classified_VBN as_IN Under_IN US_NNP GAAP_NNP the_DT Ordinary_NNP Shares_NNP of_IN the_DT Company_NN purchased_VBD extraordinary_JJ items_NNS only_RB if_IN they_PRP meet_VBP certain_JJ criteria_NNS ._.
Any_DT gain_NN or_CC loss_NN by_IN the_DT Employee_NNP Benefit_NNP Trust_NNP are_VBP accounted_VBN for_IN at_IN cost_NN as_IN treasury_NN on_IN extinguishment_NN will_MD be_VB recorded_VBN in_IN the_DT most_RBS appropriate_JJ line_NN item_NN to_TO shares_NNS which_WDT reduce_VBP shareholders_NNS funds_NNS ._.
Gains_NNS or_CC losses_NNS arising_VBG which_WDT it_PRP relates_VBZ within_IN net_JJ income_NN before_IN extraordinary_JJ items_NNS ._.
SFAS_NNP 145_CD on_IN subsequent_JJ issuance_NN of_IN the_DT shares_NNS to_TO employees_NNS are_VBP recorded_VBN as_IN is_VBZ effective_JJ for_IN fiscal_JJ years_NNS beginning_VBG after_IN 15_CD May_NNP 2002_CD ._.
However_RB ,_, certain_JJ adjustments_NNS to_TO shareholders_NNS funds_NNS ._.
The_DT reduction_NN in_IN cost_NN ,_, which_WDT is_VBZ sections_NNS are_VBP effective_JJ for_IN transactions_NNS occurring_VBG after_IN 15_CD May_NNP 2002_CD ._.
The_DT expensed_VBN under_IN UK_NNP GAAP_NNP ,_, is_VBZ reversed_VBN under_IN US_NNP GAAP_NNP to_TO maintain_VB the_DT Group_NNP does_VBZ not_RB expect_VB the_DT adoption_NN of_IN this_DT standard_NN will_MD have_VB a_DT material_NN treasury_NN shares_NNS at_IN cost_NN ._.
All_DT employee_NN compensation_NN expense_NN is_VBZ recorded_VBN impact_NN on_IN its_PRP$ financial_JJ position_NN or_CC results_NNS of_IN operations_NNS ._.
SFAS_NNP 146_CD Accounting_NNP Costs_NNS Associated_NNP with_IN Exit_NN or_CC Disposal_NNP Activities_NNPS ,_, XI_NNP Financial_NNP Instruments_NNP Under_IN UK_NNP GAAP_NNP ,_, periodic_JJ gains_NNS and_CC losses_NNS on_IN which_WDT was_VBD issued_VBN at_IN the_DT end_NN of_IN June_NNP 2002_CD ,_, addresses_NNS issues_NNS regarding_VBG interest_NN and_CC foreign_JJ currency_NN derivatives_NNS are_VBP not_RB recognized_VBN until_IN the_DT the_DT recognition_NN ,_, measurement_NN ,_, and_CC reporting_NN of_IN costs_NNS associated_VBN with_IN operational_JJ transactions_NNS to_TO which_WDT they_PRP are_VBP linked_VBN occur_VBP ._.
Under_IN US_NNP GAAP_NNP ,_, exit_NN and_CC disposal_NN activities_NNS ,_, including_VBG restructuring_NN activities_NNS ._.
This_DT the_DT Group_NNP records_NNS all_DT derivative_JJ instruments_NNS on_IN the_DT balance_NN sheet_NN at_IN fair_JJ standard_NN will_MD be_VB implemented_VBN with_IN effect_NN from_IN 1_CD January_NNP 2003_CD ._.
The_DT value_NN with_IN changes_NNS in_IN fair_JJ values_NNS are_VBP recorded_VBN in_IN earnings_NNS ._.
The_DT Group_NNP Group_NNP does_VBZ not_RB expect_VB the_DT adoption_NN of_IN this_DT standard_NN will_MD have_VB a_DT material_NN has_VBZ also_RB reviewed_VBN its_PRP$ contractual_JJ arrangements_NNS for_IN the_DT existence_NN of_IN impact_NN on_IN its_PRP$ financial_JJ position_NN or_CC results_NNS of_IN operations_NNS ._.
embedded_VBN derivatives_NNS that_WDT should_MD be_VB separately_RB accounted_VBN for_IN under_IN In_IN November_NNP 2002_CD ,_, the_DT FASB_NNP issued_VBD Interpretation_NNP No._NN ._.
If_IN embedded_VBN derivatives_NNS are_VBP identified_VBN ,_, they_PRP are_VBP recorded_VBN Guarantors_NNP Accounting_NNP and_CC Disclosure_NNP Requirements_NNP for_IN Guarantees_NNP ,_, separately_RB from_IN their_PRP$ host_NN contracts_NNS at_IN fair_JJ value_NN ,_, with_IN changes_NNS in_IN fair_JJ Including_VBG Indirect_JJ Guarantees_NNS of_IN Indebtedness_NN of_IN Others_NNS ._.
FIN_NNP 45_CD expands_VBZ value_NN recognized_VBN in_IN current_JJ earnings_NNS ._.
on_IN the_DT accounting_NN guidance_NN of_IN other_JJ SFASs_NNS FIN_NNP 45_CD elaborates_NNS on_IN the_DT XII_NNP Adoption_NN of_IN US_NNP GAAP_NNP Pronouncements_NNP On_IN 1_CD January_NNP 2002_CD the_DT Group_NNP existing_VBG disclosure_NN requirements_NNS for_IN most_JJS guarantees_NNS ,_, including_VBG loan_NN adopted_VBN SFAS_NNP No._NN ._.
142_CD Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS ._.
SFAS_NNP 142_CD guarantees_NNS such_JJ as_IN standby_JJ letters_NNS of_IN credit_NN ._.
It_PRP also_RB clarifies_VBZ that_IN at_IN the_DT requires_VBZ that_IN goodwill_NN will_MD no_RB longer_RB be_VB amortised_VBN over_IN its_PRP$ estimated_JJ time_NN a_DT company_NN issues_VBZ a_DT guarantee_NN ,_, it_PRP must_MD recognize_VB an_DT initial_JJ liability_NN useful_JJ life_NN ._.
The_DT Group_NNP must_MD instead_RB identify_VB and_CC value_VB its_PRP$ reporting_VBG units_NNS for_IN the_DT fair_JJ value_NN ,_, or_CC market_NN value_NN ,_, of_IN the_DT obligations_NNS it_PRP assumes_VBZ under_IN for_IN the_DT purpose_NN of_IN assessing_VBG ,_, at_IN least_JJS annually_RB ,_, potential_JJ impairment_NN of_IN that_DT guarantee_NN and_CC must_MD disclose_VB that_DT information_NN in_IN its_PRP$ interim_JJ and_CC goodwill_NN allocated_VBN to_TO each_DT reporting_VBG unit_NN ._.
Separate_JJ intangible_JJ assets_NNS with_IN annual_JJ financial_JJ statements_NNS ._.
FIN_NNP 45_CD will_MD be_VB implemented_VBN on_IN a_DT finite_JJ lives_NNS continue_VBP to_TO be_VB amortised_VBN over_IN their_PRP$ useful_JJ lives_NNS ._.
During_IN the_DT prospective_JJ basis_NN to_TO guarantees_NNS issued_VBN or_CC modified_VBN after_IN 31_CD December_NNP second_JJ quarter_NN of_IN 2002_CD ,_, the_DT Group_NNP completed_VBD the_DT transitional_JJ goodwill_NN 2002_CD ._.
The_DT disclosure_NN requirements_NNS in_IN this_DT Interpretation_NN are_VBP effective_JJ impairment_NN test_NN prescribed_VBN in_IN SFAS_NNP 142_CD with_IN respect_NN to_TO existing_VBG goodwill_NN ._.
forfinancial_JJ statements_NNS of_IN periods_NNS ending_VBG after_IN 15_CD December_NNP 2002_CD ._.
The_DT transitional_JJ goodwill_NN impairment_NN test_NN involved_VBD a_DT comparison_NN of_IN the_DT The_NNP Group_NNP is_VBZ currently_RB evaluating_VBG the_DT impact_NN of_IN this_DT interpretation_NN fair_JJ value_NN of_IN the_DT Groups_NNS reporting_VBG unit_NN ,_, as_IN defined_VBN under_IN SFAS_NNP 142_CD ,_, with_IN on_IN its_PRP$ financial_JJ position_NN and_CC results_NNS of_IN operations_NNS ._.
its_PRP$ carrying_VBG amount_NN as_IN of_IN the_DT adoption_NN date_NN ._.
As_IN a_DT result_NN of_IN the_DT transitional_JJ In_IN January_NNP 2003_CD ,_, the_DT FASB_NNP issued_VBD Interpretation_NNP No._NN ._.
46_CD ,_, Consolidation_NN impairment_NN tests_NNS performed_VBN as_IN of_IN 1_CD January_NNP 2002_CD ,_, there_EX was_VBD no_DT indicator_NN of_IN Variable_JJ Interest_NN Entities_NNS FIN_NNP 46_CD ._.
Under_IN this_DT interpretation_NN ,_, certain_JJ of_IN goodwill_NN impairment_NN ._.
entities_NNS known_VBN as_IN Variable_JJ Interest_NN Entities_NNS VIE_VBP must_MD be_VB consolidated_JJ If_IN the_DT Group_NNP had_VBD accounted_VBN for_IN goodwill_NN under_IN SFAS_NNP 142_CD for_IN the_DT year_NN by_IN the_DT primary_JJ beneficiary_NN of_IN the_DT entity_NN ._.
The_DT primary_JJ beneficiary_NN is_VBZ ended_VBN 31_CD December_NNP 2001_CD ,_, the_DT impact_NN on_IN reported_VBN US_NNP GAAP_NNP results_NNS generally_RB defined_VBN as_IN having_VBG the_DT majority_NN of_IN the_DT risks_NNS and_CC rewards_NNS arising_VBG would_MD have_VB been_VBN as_IN follows_VBZ :_: from_IN the_DT VIE_NNP ._.
For_IN VIEs_NNS in_IN which_WDT a_DT significant_JJ but_CC not_RB majority_NN variable_JJ interest_NN is_VBZ held_VBN ,_, certain_JJ disclosures_NNS are_VBP required_VBN ._.
The_DT measurement_NN 000_CD principles_NNS of_IN this_DT interpretation_NN will_MD be_VB effective_JJ for_IN the_DT Groups_NNS Net_JJ loss_NN under_IN US_NNP GAAP_NNP 43,868_CD 31_CD December_NNP 2003_CD financial_JJ statements_NNS ._.
The_DT Group_NNP is_VBZ currently_RB assessing_VBG the_DT impact_NN of_IN this_DT interpretation_NN on_IN its_PRP$ financial_JJ position_NN Add_VB :_: Goodwill_NNP amortisation_NN 8,552_CD and_CC results_NNS of_IN operations_NNS ._.
Adjust_VB net_JJ loss_NN under_IN US_NNP GAAP_NNP 35,316_CD Adjusted_VBN basic_JJ and_CC diluted_JJ loss_NN per_IN Ordinary_NNP Share_NNP under_IN US_NNP GAAP_NNP pence_NN 6.7_CD p_NN On_IN 1_CD January_NNP 2002_CD the_DT Group_NNP adopted_VBD SFAS_NNP No._NN ._.
144_CD ,_, Accounting_NNP for_IN the_DT Impairment_NN or_CC Disposal_NN of_IN Long-Lived_NNP Assets_NNPS ._.
SFAS_NNP 144_CD develops_VBZ one_CD accounting_NN model_NN for_IN long-lived_JJ assets_NNS ,_, including_VBG discontinued_VBN operations_NNS to_TO be_VB disposed_VBN of_IN by_IN sale_NN ._.
It_PRP requires_VBZ that_IN all_DT long-lived_JJ assets_NNS be_VB measured_VBN at_IN the_DT lower_JJR of_IN carrying_VBG amount_NN or_CC fair_JJ value_NN less_RBR cost_VBN to_TO sell_VB whether_IN reported_VBN in_IN continuing_VBG or_CC discontinued_VBN operations_NNS ._.
The_DT adoption_NN of_IN SFAS_NNP 144_CD has_VBZ not_RB had_VBD a_DT material_NN impact_NN on_IN the_DT Groups_NNS financial_JJ position_NN or_CC results_NNS of_IN operations_NNS ._.
reconciliation_NN to_TO US_NNP 84_CD accounting_NN principles_NNS continued_VBD SkyePharma_NNP annual_JJ report_NN 2002_CD Company_NN information_NN and_CC advisors_NNS Registered_NNP and_CC Head_NNP Office_NNP Joint_NNP Corporate_NNP Brokers_NNPS 105_CD Piccadilly_NNP ,_, Merrill_NNP Lynch_NNP International_NNP London_NNP W1J_NNP 7NJ_NNP Ropemaker_NNP Place_NNP Telephone_NNP :_: 020 7491 1777_CD 25_CD Ropemaker_NNP Street_NNP Fax_NNP :_: 020 7491 3338_CD London_NNP EC2Y_NNP 9LY_NNP Registered_NNP No_NNP :_: 107582_CD Secretary_NNP :_: Douglas_NNP Parkhill_NNP Socit_NNP Gnrale_NNP Exchange_NNP House_NNP Auditors_NNS Primrose_NNP Street_NNP LLP_NNP London_NNP EC4A_NNP 2DD_NNP Chartered_NNP Accountants_NNPS 1_CD Embankment_NNP Place_NNP Bankers_NNP London_NNP WC2N_NNP 6RH_NNP National_NNP Westminster_NNP Bank_NNP plc_NN Bishopsgate_NNP Business_NNP Centre_NNP Solicitors_NNPS PO_NNP Box_NNP 34_CD UK_NNP 15_CD Bishopsgate_NNP Stringer_NNP Saul_NNP London_NNP EC2P_NNP 2AP_NNP 17_CD Hanover_NNP Square_NNP London_NNP W1S_NNP 1HU_NNP Registrars_NNPS Capita_NNP Registrars_NNPS US_NNP Bourne_NNP House_NNP Sullivan_NNP &_CC Cromwell_NNP 34_CD Beckenham_NNP Road_NNP St._NNP Olaves_NNP House_NNP Beckenham_NNP 9a_CD Ironmonger_NNP Lane_NNP Kent_NNP BR3_NNP 4TU_NNP London_NNP EC2V_NNP 8EY_NNP Depository_NNP Investment_NNP Bankers_NNPS The_NNP Bank_NNP of_IN New_NNP York_NNP Merrill_NNP Lynch_NNP International_NNP 101_CD Barclay_NNP Street_NNP Ropemaker_NNP Place_NNP New_NNP York_NNP 25_CD Ropemaker_NNP Street_NNP NY_NNP 10286_CD London_NNP EC2Y_NNP 9LY_NNP USA_NNP Designed_NNP and_CC produced_VBN by_IN Addison_NNP www_NN ._.
